Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

Cancer Letters

Volumn 358, Issue 2, 2015, Pages 100-106

  Kareva, Irina ^a,b   Waxman, David J ^c   Klement, Giannoula Lakka ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c USA   (United States)

Author keywords

Angiogenesis; Anti tumor immunity; Mechanisms of metronomic chemotherapy; MTDL alternative; Therapeutic resistance

Indexed keywords

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CELL ACTIVITY; CELL MATURATION; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; INNATE IMMUNITY; LOW DRUG DOSE; LYMPHOCYTE; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; NONHUMAN; SHORT SURVEY; THERAPY RESISTANCE; TUMOR ASSOCIATED ENDOTHELIAL CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; IMMUNE SYSTEM; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENT;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84921558645     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.039     Document Type: Review

References (98)

1. Skipper H.E., Schabel F.M., Mellett L.B., Montgomery J.A., Wilkoff L.J., Lloyd H.H., et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep 1970, 54:431-450.
2. Pizzo P.A., Poplack D.G. Principles and Practice of Pediatric Oncology 2010, Lippincott Williams & Wilkins, Philadelphia. sixth ed.
3. Bower M., Paradinas F.J., Fisher R.A., Nicholson S.K., Rustin G.J., Begent R.H., et al. Placental site trophoblastic tumor: molecular analysis and clinical experience. Clin. Cancer Res 1996, 2:897-902.
4. Murugaesu N., Schmid P., Dancey G., Agarwal R., Holden L., McNeish I., et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J. Clin. Oncol 2006, 24:4862-4866.
5. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med 1987, 316:1435-1440.
6. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med 1998, 339:1506-1514.
7. Huang H.H., Xiao F., Chen F.Y., Wang T., Li J.M., Wang J.M., et al. Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: a multicentre study. Exp. Ther. Med 2012, 4:475-480.
8. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
9. Andre N., Abed S., Orbach D., Alla C.A., Padovani L., Pasquier E., et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011, 2:960-965.
10. Pasquier E., Andre N. New therapeutic advances and perspectives in tumour angiogenesis. Curr. Cancer Drug Targets 2010, 10:877-878.
11. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol 2010, 7:455-465.
12. Pasquier E., Kieran M.W., Sterba J., Shaked Y., Baruchel S., Oberlin O., et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl. Oncol 2011, 4:203-211.
13. Savage P., Stebbing J., Bower M., Crook T. Why does cytotoxic chemotherapy cure only some cancers?. Nat. Clin. Pract. Oncol 2009, 6:43-52.
14. Andre N., Carre M., Pasquier E. Metronomics: towards personalized chemotherapy?. Nat. Rev. Clin. Oncol 2014, 11:413-431.
15. Bouche G., Andre N., Banavali S., Berthold F., Berruti A., Bocci G., et al. Lessons from the fourth metronomic and anti-angiogenic therapy meeting, 24-25 June 2014. Milan Ecancermedicalscience 2014, 8:463.
16. Hafner C., Reichle A., Vogt T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPAR agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr. Cancer Drug Targets 2005, 5:393-419.
17. Romiti A., Cox M.C., Sarcina I., Di Rocco R., Antonio C.D., Barucca V., et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother. Pharmacol 2013, 72:13-33.
18. M. Koopman, L. Simkens, A. May, L. Mol, H.V. Tinteren, C.J.A. Punt, Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). In: 2014 Gastrointestinal Cancers Symposium, 2014.
19. Andre N., Banavali S., Snihur Y., Pasquier E. Has the time come for metronomics in low-income and middle-income countries?. Lancet Oncol 2013, 14:e239-e248.
20. Bocci G., Francia G. Metronomic Chemotherapy 2014, Springer.
21. Lien K., Georgsdottir S., Sivanathan L., Chan K., Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur. J. Cancer 2013, 49:3387-3395.
22. Maiti R. Metronomic chemotherapy. J. Pharmacol. Pharmacother 2014, 5:186-192.
23. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
24. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
25. A. Gatenby Robert, In: "Antibiotic Resistance Questions & Answers" [Are antibacterial-containing products (soaps, household cleaners, etc.) better for preventing the spread of infection? Does their use add to the problem of resistance?], 2011. Atlanta, Georgia.
26. Gatenby R.A. A change of strategy in the war on cancer. Nature 2009, 459:508-509.
27. Gatenby R.A., Brown J., Vincent T. Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 2009, 69:7499-7502.
28. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med 2011, 17:320-329.
29. Klement G.L., Yip T.T., Cassiola F., Kikuchi L., Cervi D., Podust V., et al. Platelets actively sequester angiogenesis regulators. Blood 2009, 113:2835-2842.
30. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
31. Gerhardt H., Betsholtz C. How do endothelial cells orientate?. EXS 2005, 3-15.
32. Blanco R., Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb. Perspect. Med 2013, 3:a006569.
33. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008, 4:241-246.
34. Jakobsson L., Bentley K., Gerhardt H. VEGFRs and notch: a dynamic collaboration in vascular patterning. Biochem. Soc. Trans 2009, 37:1233-1236.
35. Dawson D.W., Bouck N. Thrombospondin as an inhibitor of angiogenesis. Thrombospodin 1999, 185-203. Humana Press, Totowa, NJ. B.A. Teicher (Ed.).
36. Klement G.S.E.V.D. The role of platelets in angiogenesis. Platelets 2012, Elsevier/Academic Press, San Diego, CA. A. Michelson (Ed.).
37. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3609-3614.
38. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995, 14:263-277.
39. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J., et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000, 60:490-498.
40. Shih T., Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther 2006, 28:1779-1802.
41. Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol 2001, 2:733-740.
42. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest 2000, 105:R15-R24.
43. Scharovsky O.G., Mainetti L.E., Rozados V.R. Metronomic chemotherapy: changing the paradigm that more is better. Curr. Oncol 2009, 16:7-15.
44. Hida K., Ohga N., Akiyama K., Maishi N., Hida Y. Heterogeneity of tumor endothelial cells. Cancer Sci 2013, 104:1391-1395.
45. Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico B., Ria R., et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999, 94:4143-4155.
46. Vacca A., Ribatti D., Iurlaro M., Merchionne F., Nico B., Ria R., et al. Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res 2002, 11:103-118.
47. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res 2002, 8:221-232.
48. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13:31-36.
49. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
50. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
51. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
52. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol 2006, 1:119-150.
53. Bello L., Carrabba G., Giussani C., Lucini V., Cerutti F., Scaglione F., et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001, 61:7501-7506.
54. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
55. Hida K., Akiyama K., Ohga N., Maishi N., Hida Y. Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J. Biochem 2013, 153:243-249.
56. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev 2010, 74:417-433.
57. Folkins C., Man S., Xu P., Shaked Y., Hicklin D.J., Kerbel R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007, 67:3560-3564.
58. Vives M., Ginesta M.M., Gracova K., Graupera M., Casanovas O., Capella G., et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int. J. Cancer 2013, 133:2464-2472.
59. Galluzzi L., Senovilla L., Zitvogel L., Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov 2012, 11:215-233.
60. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol 2008, 8:59-73.
61. Banissi C., Ghiringhelli F., Chen L., Carpentier A.F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother 2009, 58:1627-1634.
62. Generali D., Bates G., Berruti A., Brizzi M.P., Campo L., Bonardi S., et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin. Cancer Res 2009, 15:1046-1051.
63. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother 2007, 56:641-648.
64. Tanaka H., Matsushima H., Nishibu A., Clausen B.E., Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 2009, 69:6987-6994.
65. Tanaka H., Matsushima H., Mizumoto N., Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res 2009, 69:6978-6986.
66. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res 2005, 11:6713-6721.
67. Nars M.S., Kaneno R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int. J. Cancer 2013, 132:2471-2478.
68. Doloff J.C., Waxman D.J. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012, 72:1103-1115.
69. Chen C.S., Doloff J.C., Waxman D.J. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014, 16:84-96.
70. Wu J., Waxman D.J. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett 2014, 353:272-280.
71. Doloff J.C., Chen C.S., Waxman D.J. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol. Cancer 2014, 13:158.
72. Young S.D., Whissell M., Noble J.C., Cano P.O., Lopez P.G., Germond C.J. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin. Cancer Res 2006, 12:3092-3098.
73. Jia L., Waxman D.J. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett 2013, 330:241-249.
74. Halama N., Braun M., Kahlert C., Spille A., Quack C., Rahbari N., et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res 2011, 17:678-689.
75. Klement G.L., Kamen B.A. Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?. J. Pediatr. Hematol. Oncol 2011, 33:1-3.
76. Toyoda Y., Manabe A., Tsuchida M., Hanada R., Ikuta K., Okimoto Y., et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J. Clin. Oncol 2000, 18:1508-1516.
77. Dekker A.W., van't Veer M.B., Sizoo W., Haak H.L., van der Lelie J., Ossenkoppele G., et al. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J. Clin. Oncol 1997, 15:476-482.
78. Peyrl A., Chocholous M., Kieran M.W., Azizi A.A., Prucker C., Czech T., et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr. Blood Cancer 2012, 59:511-517.
79. Wernli M., Tichelli A., von Fliedner V., Brun del Re G., Chapuis B., Fey M.F., et al. Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: a pilot assessment. Working Party on Leukaemia of the Swiss Group for Epidemiologic and Clinical Cancer Research (SAKK). Br. J. Haematol 1994, 87:39-43.
80. Choi L.M., Rood B., Kamani N., La Fond D., Packer R.J., Santi M.R., et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr. Blood Cancer 2008, 50:970-975.
81. Cervi D., Yip T.T., Bhattacharya N., Podust V.N., Peterson J., Abou-Slaybi A., et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008, 111:1201-1207.
82. Mayer E.L., Isakoff S.J., Klement G., Downing S.R., Chen W.Y., Hannagan K., et al. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res. Treat 2012, 136:169-178.
83. Peterson J.E., Zurakowski D., Italiano J.E., Michel L.V., Connors S., Oenick M., et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15:265-273.
84. Peterson J.E., Zurakowski D., Italiano J.E., Michel L.V., Fox L., Klement G.L., et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am. J. Hematol 2010, 85:487-493.
85. Tang J.H., Zhao J.H., Lu J.W., Yan F., Qin J.W., Xu B. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. J. Cancer Res. Clin. Oncol 2011, 137:55-63.
86. Treiber G., Wex T., Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J. Cancer Res. Clin. Oncol 2009, 135:271-281.
87. Allegrini G., Falcone A., Fioravanti A., Barletta M.T., Orlandi P., Loupakis F., et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 2008, 98:1312-1319.
88. Orlandi P., Fontana A., Fioravanti A., Di Desidero T., Galli L., Derosa L., et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br. J. Cancer 2013, 109:957-964.
89. Allegrini G., Di Desidero T., Barletta M.T., Fioravanti A., Orlandi P., Canu B., et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 2012, 15:275-286.
90. Zloza A., Kim D.W., Kim-Schulze S., Jagoda M.C., Monsurro V., Marincola F.M., et al. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J. Immunother. Cancer 2014, 2:1.
91. Perroud H.A., Rico M.J., Alasino C.M., Pezzotto S.M., Rozados V.R., Scharovsky O.G. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer. Indian J. Cancer 2013, 50:115-121.
92. Colleoni M., Orlando L., Sanna G., Rocca A., Maisonneuve P., Peruzzotti G., et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol 2006, 17:232-238.
93. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nole F., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol 2002, 13:73-80.
94. Manso L., Valdiviezo N., Sepulveda J., Ciruelos E., Mendiola C., Ghanem I., et al. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clin. Transl. Oncol 2013, 15:467-471.
95. Montagna E., Cancello G., Bagnardi V., Pastrello D., Dellapasqua S., Perri G., et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin. Breast Cancer 2012, 12:207-214.
96. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006, 66:3386-3391.
97. Munoz R., Shaked Y., Bertolini F., Emmenegger U., Man S., Kerbel R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005, 14:466-479.
98. Barbolosi D., Ciccolini J., Meille C., Elharrar X., Faivre C., Lacarelle B., et al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother. Pharmacol 2014, 74:647-652.